Yozo Nakazawa

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Introduction Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is highly prevalent in Asia. This study evaluated the safety and efficacy of a risk‐stratified treatment guided by dexamethasone (DEX) response and plasma EBV‐DNA levels. Our goal was to optimize etoposide dosing and establish a safer EBV‐HLH treatment. Methods We conducted a single‐arm, multicenter, risk‐stratified Phase II clinical trial, EBV‐HLH15, for EBV‐HLH. Patients were classified into three groups based on age, DEX response, and plasma EBV‐DNA load. In the low‐risk (LR) group, etoposide was eliminated from the treatment regimen. In the intermediate‐risk and high‐risk group (IR/HR group), etoposide dosing was reduced by up to 60% compared with the HLH‐2004 study to attenuate treatment intensity, whereas rituximab was added in the HR group to maintain it. Results Of 56 patients suspected of EBV‐HLH enrolled, 26 (14 in LR, eight in IR, and four in HR group) were eligible for EBV‐HLH15. The median age was 3.5 years (range: 1.0–8.0). The 1‐year overall survival of the LR and IR/HR groups was 100% and 81.5% (95% confidence interval [CI] = 43.5–95.1), respectively. The event‐free survival of the LR and IR/HR groups was 78.6% (95% CI = 47.2–92.5) and 58.3% (95% CI = 27.0–80.1), respectively. Most events (9/10, mainly deterioration or recurrence of HLH) occurred within 3 weeks of treatment initiation. No patients received rituximab as scheduled in Weeks 5 and 6. Conclusion Risk‐stratified treatment for EBV‐HLH guided by DEX response and plasma EBV‐DNA levels after 2 weeks of treatment was safe and effective.

Year:

2025

Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cytometric analysis of GD2-2840z-CARTs and GD2-CARrejTs to evaluate CAR transgene expression and LMP2 antigen specificity. Histogram in blue, fluorescence minus one (FMO) control. Histogram in red, GD2-2840z-CARTs and GD2-CARrejTs. The plots represent three independent experiments. C, Intracellular perforin and granzyme B marking, GD2-2840z-CARTs and GD2-CARrejTs (red). Histogram in blue, FMO control. The plots represent three independent experiments. D, CBA for measuring cytokines (IFNγ, TNF, and IL2) produced by effector T cells (GD2-2840z-CARTs and GD2-CARrejTs) after 24 hours of coculture with SCLC-J1. Error bars represent ± SEM. E, Representative flow cytometrogram of memory phenotype (CD45RA and CD62 L population) among GD2-2840-CARTs and GD2-CARrejTs. F, In vitro 51 Cr assays of GD2-2840z-CARTs, GD2-CARrejTs, and control T cells against SCLC cell lines. Error bars represent ± SD. Data represent three independent triplicate experiments. G, RTCA continuous graphical output of tumor proliferation indices up to 40 hours for H69 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments. H, RTCA continuous graphical output of tumor proliferation indices up to 100 hours for H446 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments.

Year:

2024

Blockade of TIGIT and PD-1 augments cytotoxicity of GD2 2840z-CARTs. A, Schema of immune-regulatory mechanism of T cells against SCLC. B, Flow cytometric analysis of TIGIT and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs. The plots represent independent triplicate experiments. C, Flow cytometric analysis of CD155 expression on H69, H446, and SCLC-J1 (red). Histogram in blue, fluorescence minus one (FMO) control. The histograms represent independent triplicate experiments. D, Flow cytometric analysis of PD-L1 expression on GD2-expressing tumor cell lines (H69, H446, and SCLC-J1; red). Histogram in blue, FMO control. The histograms represent independent triplicate experiments. E, RTCA continuous graphical output of tumor proliferation indices up to 80 hours alone and in coculture with GD2-2840z-CARTs with/without anti-TIGIT (aTIGIT) and/or anti-PD-1 antibodies (aPD-1). Data were plotted and are shown as mean ± SD. Data represent three independent triplicate experiments. F, Schema of immune-regulatory mechanism of GD2-2840z-CARTs and GD2-CARrejTs against SCLC.

Year:

2024

Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cytometric analysis of GD2-2840z-CARTs and GD2-CARrejTs to evaluate CAR transgene expression and LMP2 antigen specificity. Histogram in blue, fluorescence minus one (FMO) control. Histogram in red, GD2-2840z-CARTs and GD2-CARrejTs. The plots represent three independent experiments. C, Intracellular perforin and granzyme B marking, GD2-2840z-CARTs and GD2-CARrejTs (red). Histogram in blue, FMO control. The plots represent three independent experiments. D, CBA for measuring cytokines (IFNγ, TNF, and IL2) produced by effector T cells (GD2-2840z-CARTs and GD2-CARrejTs) after 24 hours of coculture with SCLC-J1. Error bars represent ± SEM. E, Representative flow cytometrogram of memory phenotype (CD45RA and CD62 L population) among GD2-2840-CARTs and GD2-CARrejTs. F, In vitro 51 Cr assays of GD2-2840z-CARTs, GD2-CARrejTs, and control T cells against SCLC cell lines. Error bars represent ± SD. Data represent three independent triplicate experiments. G, RTCA continuous graphical output of tumor proliferation indices up to 40 hours for H69 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments. H, RTCA continuous graphical output of tumor proliferation indices up to 100 hours for H446 cells cocultured with control T cells, GD2-2840z-CARTs, and GD2-CARrejTs and for tumor only; E:T ratio uniformly 1:1. Data were plotted and are shown as mean ±SD. Data represent three independent triplicate experiments.

Year:

2024

Generation of GD2-CARTs. A, GD2 expression by NSCLC cell line (negative control) and by four SCLC cell lines (red), with isotype control (blue). The plots represent three independent experiments. B, Schema, lentiviral GD2-CAR-vectors containing Ubc promoter. CAR contains an scFv derived from heavy (VH) and light chain (VL) variable regions of 14G2a mAb. TM, transmembrane. Each CAR has a costimulatory domain (highlighted in red): GD2-2840z, CD28 and OX40; GD2-28z, CD28; and GD2-BBz, 4-1BB. The constructs contain the cleavable 2A-like sequence and mCherry. C, Flow cytometric analysis, GD2-CAR transgene expression in GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs (red). Fluorescence minus one (FMO) control (blue). The histogram represents three independent experiments. D, Flow cytometric analysis, expression of LAG-3, PD-1, and TIM-3 on day 12 after transduction. Error bars represent ± SD. Data represent triplicate experiments. *, P P P E, In vitro 51 Cr release assay of GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs (effectors) against GD2 + tumor cells (NK-YS). Error bars represent ± SD. Data represent triplicate experiments. F, In vitro 51 Cr release assay of GD2-2840z-CARTs against GD2 + SCLC. Error bars represent ± SD. Data represent three independent triplicate experiments. G, Flow cytometric analysis, MFI of GD2 on GD2-expressing tumors. Error bars represent ± SD. The bars represent triplicate experiments. H, In vitro 51 Cr release assay of GD2-2840z-CARTs against SCLC cell lines. Error bars represent ± SD. Data represent triplicate experiments.

Year:

2024

Supplementary Figure S4 presents flow cytometric analysis of PD-1, TIGIT, and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs after coculture with SCLC-J1 cells, based on three independent experiments. It also features real-time cell analysis (RTCA) showing tumor proliferation indices over 80 hours in various conditions: alone, in coculture with GD2-CARrejTs, and control T cells, with and without anti-TIGIT and anti-PD-1 antibodies. The data illustrate the effect of these treatments on tumor growth.

Year:

2024

Supplementary Figure S2 showcases the functional and phenotypic analysis of GD2-CARTs and GD2-CARrejTs, including cytokine production (IL-4, IL-6, IL-10, and IL-17A) through cytometric bead assays, flow cytometry gating strategies, memory phenotype subsets, CAR transgene expression, and CD4/8 ratios.

Year:

2024

Robust tumor suppressive effect of GD2-CARrejTs in vivo. A, Graphical abstract of in vivo experiment. H446 cells labeled with FFluc/GFP were intravenously injected into NOG mice (1 × 10 6 cells/mouse) 4 days before treatment. Mice treated with GD2-2840z-CARTs and GD2-CARrejTs were treated every 2 weeks (three doses). B, Bioluminescence imaging of mice engrafted with H446 cells in three groups: no treatment group (control group, n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). Images of all mice from each group of three independent experiments are shown. C, Tumor burden of each mouse is shown, comparing the in vivo efficacy of GD2-2840z-CARTs and GD2-CARrejTs. Bioluminescence kinetics of all mice from each group of three independent experiments are shown: no treatment group (control group, n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). D, Quantitation of tumor burden on day 35 is shown: no treatment group ( n = 8), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). ****, P E, Kaplan–Meier curves representing percentage survival of groups: no treatment group ( n = 10), GD2-2840z-CARTs group ( n = 7), and GD2-CARrejTs group ( n = 7). ***, P P F, Copy numbers of GD2-CAR transduced T cells in mouse treated with GD2-2840z-CARTs and GD2-CARrejTs on day 35. Error bars represent ± SD. The plots represent three independent experiments. G, Photomicrographs, representative hematoxylin and eosin–stained sections of liver of SCLC-bearing mouse in each group; no treatment, GD2-2840z-CART treatment, and GD2-CARrejT treatment (top row). Infiltrates are bracketed. Human CD3 + T-cell infiltrates in liver (bottom row). CD3 + T cells are stained in brown (black arrowhead). 4x, 40x: Objective lens. Scale bars, each 20 µm.

Year:

2024

Supplementary Figure S4 presents flow cytometric analysis of PD-1, TIGIT, and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs after coculture with SCLC-J1 cells, based on three independent experiments. It also features real-time cell analysis (RTCA) showing tumor proliferation indices over 80 hours in various conditions: alone, in coculture with GD2-CARrejTs, and control T cells, with and without anti-TIGIT and anti-PD-1 antibodies. The data illustrate the effect of these treatments on tumor growth.

Year:

2024

Supplementary Figure S1 illustrates the cytotoxic effects of GD2-CARTs (GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs) and control T cells on GD2+ tumor cells through in vitro 51Cr release assays.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (6)

Satoshi Yamazaki

Prof

University of Tokyo

JAPAN
View details

Koichi Ohshima

Professor

Kurume University

JAPAN
View details

Miki Ando

Juntendo University Graduate School of Medicine

JAPAN
View details

Hirokazu Kanegane

Tokyo Medical and Dental University

JAPAN
View details

Kazuhisa Takahashi

Professor

Juntendo University Graduate School of Medicine

JAPAN
View details

Hiromitsu Nakauchi

Distinguished University Professor

Tokyo Medical and Dental University

JAPAN
View details